Ankylosing spondylitis (AS) is a chronic, progressive inflammatory disease that primarily affects the spine and sacroiliac joints. The onset of AS is typically in the third decade of life. AS has a standardised prevalence rate of 0.55% among white patients[@b1] and is linked with HLA-B27 positivity.[@b2] Patients with AS can experience significant long-term functional impairment and disability, with reduced quality of life and an increased risk of comorbid conditions. AS is associated with significant direct and indirect costs to the patient and the healthcare system.[@b3]

The essential role of tumour necrosis factor (TNF) in AS has been shown by the efficacy of TNF blockade in the treatment of AS. The efficacy of TNF antagonists, adalimumab, etanercept and infliximab, has been demonstrated in short-term clinical studies,[@b4]^--^[@b10] as well as in long-term studies of etanercept (up to 2 years)[@b11] [@b12] and infliximab (up to 3 years).[@b13]^--^[@b15]

The Adalimumab Trial Evaluating Long-term Efficacy and Safety for AS (ATLAS) demonstrated that adalimumab, a fully human anti-TNF monoclonal antibody, improves the signs and symptoms of AS for up to 24 weeks and is generally well tolerated.[@b16] During short-term treatment, adalimumab also improved the health-related quality of life (HRQoL) and physical function of patients with AS.[@b17] In addition, adalimumab reduced pain, fatigue and stiffness, three of the most common concerns of patients with AS.[@b18] Patients completing the 24-week, placebo controlled, double-blind portion of ATLAS were eligible for enrollment in an open-label extension study (which is still ongoing) designed to determine the safety and efficacy of adalimumab treatment in patients with active AS and the impact of adalimumab on HRQoL during up to 4.5 years of treatment. Herein, we report the 2-year interim results of this open-label extension study.

METHODS {#s2}
=======

Patients {#s2a}
--------

Patients were 18 years of age or older, diagnosed with definitive AS based on the modified New York criteria[@b19] and fulfilling at least two of the following three criteria: (1) Bath AS Disease Activity Index (BASDAI) score 4 or greater; (2) morning stiffness for 1 h or longer and (3) visual analogue scale (VAS) score for total back pain 4 or greater on a scale of 0 to 10. Patients also had an inadequate response to at least one non-steroidal anti-inflammatory drug and may (but were not required to) have failed treatment with at least one disease-modifying antirheumatic drug. Additional inclusion and exclusion criteria have been published previously.[@b16]

Study design {#s2b}
------------

Detailed efficacy, HRQoL and safety methods for the first 24-week period of the ATLAS study have been published previously.[@b16] [@b17] Patients were randomly assigned in a 2 : 1 ratio to receive either a subcutaneous injection of adalimumab (Humira; Abbott Laboratories, Abbott Park, Illinois, USA) 40 mg every other week (eow) or matching placebo during the initial 24-week, randomised, double-blind, placebo controlled period. Based on evaluation by the investigator, patients who did not achieve at least a 20% response according to the Assessment in SpondyloArthritis International Society (ASAS) criteria for improvement (ASAS20) at double-blind weeks 12, 16, or 20 had the following three options: (1) continue blinded study medication to week 24; (2) receive early-escape therapy (ie, open-label adalimumab 40 mg eow before week 24); or (3) discontinue from the study. Patients who did not achieve an ASAS20 response after 12 weeks or more of open-label treatment may have been treated with adalimumab 40 mg every week. The 24-week, double-blind study period was followed by an open-label extension phase, during which all patients received adalimumab 40 mg eow or weekly for up to an additional 4.5 years. Clinic visits occurred every 6 weeks through the double-blind period and then at weeks 30, 40, 52, 64, 76, 88 and 104.

Measures {#s2c}
--------

The primary efficacy assessment in the randomised, controlled portion of ATLAS was the ASAS20.[@b20] The ASAS40, ASAS 5/6, and ASAS-defined partial remission responses[@b21] were also evaluated. For the determination of ASAS 5/6 responses, C-reactive protein (CRP) concentrations were used as the acute phase reactant and the Bath AS Metrology Index (BASMI) was used as the metrology assessment.[@b22] Additional efficacy endpoints for ATLAS were previously described in detail[@b16] and included the patient's global assessment of disease activity during the past week, represented by the score on a 0--10 cm horizontal VAS; pain, as represented by the total back pain score on a 0--10 cm VAS; the Bath AS Functional Index (BASFI) score (0--10 cm VAS);[@b23] inflammation, as determined by the mean of the severity and duration of morning stiffness based on 0--10 cm VAS scores (mean of questions 5 and 6 of the BASDAI);[@b24] the BASMI score (0--10); CRP concentrations; BASDAI 50 response; and enthesitis, as assessed by the Maastricht AS Enthesitis Score (MASES; range 0--13).[@b25]

HRQoL measures were also completed at baseline, at weeks 12 and 24[@b17] and after 1 and 2 years of adalimumab exposure, and included the AS Quality of Life (ASQoL) questionnaire[@b26] as well as the Short Form 36 Health Survey (SF-36). The ASQoL is a disease-specific instrument designed to measure HRQoL in patients with AS and has 18 yes or no questions with a total score of 0--18. Lower ASQoL scores represent a better AS-specific HRQoL, and a reduction of at least 1.8 points was defined a priori as the minimum clinically important difference (MCID). Patients completed the SF-36 version 1 based on a 4-week recall period.[@b27] Differences of 3.0 or more points in the SF-36 physical component summary (PCS) or mental component summary (MCS) exceed the a priori definition for MCID and are considered to be clinically meaningful. Adverse events (AE), vital signs, physical examinations and laboratory assessments were routinely evaluated.

Statistical analysis {#s2d}
--------------------

The data cutoff for the 2-year interim analysis of the open-label extension of ATLAS occurred 2 years after the last patient's first visit in the study (that is, the start of the double-blind period). Data are reported based on adalimumab exposure for each patient, which was defined beginning with the first dose of adalimumab administered either during the double-blind period or the open-label period of the study. Because some patients were treated with placebo for the first 24 weeks of the study, not all patients had 2 years of exposure to adalimumab at the time of this analysis. If a patient received placebo during the double-blind period of ATLAS, efficacy and HRQoL data collected during that period were not included in this analysis of the efficacy of long-term adalimumab treatment. Only efficacy data collected following a patient's first dose of adalimumab are presented. For all efficacy and HRQoL measures, baseline for all analyses was defined as the last observation before the first dose of adalimumab. Efficacy results presented for the 2-year open-label extension are presented as observed data for all patients who received at least one dose of adalimumab; last observation carried forward (LOCF) analyses are also presented for all patients who received at least one dose of adalimumab. Safety assessments were based on observed data reported following any adalimumab exposure.

RESULTS {#s3}
=======

Patient enrollment and disposition {#s3a}
----------------------------------

The data for this study were collected between 27 January 2004 and 10 July 2006. Of the 315 patients enrolled in the double-blind period, 208 were randomly assigned to receive adalimumab 40 mg eow, 107 were assigned to receive placebo; 296 completed the 24-week double-blind period.[@b16] At baseline of the double-blind period, the mean BASDAI scores for both placebo and adalimumab groups were 6.3 (SD 1.7). Of the 311 patients who received at least one dose of adalimumab (either during the randomised, controlled portion of ATLAS or during the open-label extension), 261 (83.9%) were receiving adalimumab treatment in the open-label extension study at the time this analysis was completed.

Demographic and clinical characteristics {#s3b}
----------------------------------------

Patients were primarily male (74.9%), white (96.1%), and HLA-B27 positive (78.8%). The mean patient age was 42.3 years (SD 11.56, range 18--71). The mean duration of disease was 11.0 years (SD 9.5, range 0.1--48.4). Baseline clinical characteristics for the randomised, double-blind study[@b16] and the current extension study are displayed in [table 1](#ard-68-06-0922-t01){ref-type="table"}.

###### Summary of mean values of clinical signs and symptoms during long-term adalimumab treatment\*

  Assessment                                                              Baseline value at randomisation   Duration of adalimumab exposure                                                                                                                   
  ---------------------------------------------------------------------- --------------------------------- --------------------------------- --------------- --------------- --------------- ---------------- --------------- --------------- --------------- ---------------
  Patient's global assessment of disease activity, 0--10 cm VAS                                                                                                                                                                                               
      Baseline value                                                                 6.5 (2.0)                         6.3 (2.2)              6.2 (2.3) 303   6.2 (2.3) 309   6.2 (2.3) 291   6.2 (2.3) 309    6.2 (2.3) 275   6.2 (2.3) 309   6.3 (2.1) 172   6.2 (2.3) 309
      Visit value                                                                                                                             3.6 (2.8) 303   3.7 (2.8) 309   3.1 (2.6) 291   3.2 (2.7) 309    2.8 (2.6) 275   3.1 (2.8) 309   2.3 (2.5) 172   2.9 (2.8) 309
  Total back pain, 0--10 cm VAS                                                                                                                                                                                                                               
      Baseline value                                                                 6.7 (2.2)                         6.4 (2.2)              6.2 (2.4) 304   6.2 (2.4) 310   6.2 (2.4) 292   6.2 (2.4) 310    6.2 (2.4) 276   6.2 (2.4) 310   6.4 (2.1) 173   6.2 (2.4) 310
      Visit value                                                                                                                             3.7 (2.9) 304   3.8 (2.9) 310   3.1 (2.7) 292   3.2 (2.7) 310)   2.7 (2.6) 276   3.1 (2.8) 310   2.2 (2.5) 173   2.9 (2.9) 310
  BASFI, 0--10 cm VAS                                                                                                                                                                                                                                         
      Baseline value                                                                 5.6 (2.2)                         5.2 (2.2)              5.2 (2.4) 292   5.2 (2.4) 310   5.2 (2.3) 292   5.2 (2.4) 310    5.2 (2.4) 276   5.2 (2.4) 310   5.3 (2.2) 173   5.2 (2.4) 310
      Visit value                                                                                                                             3.5 (2.6) 305   3.6 (2.6) 310   3.1 (2.5) 292   3.2 (2.5) 310    2.8 (2.5) 276   3.1 (2.6) 310   2.4 (2.3) 173   2.9 (2.5) 310
  Inflammation (mean of questions 5 and 6 of the BASDAI), 0--10 cm VAS                                                                                                                                                                                        
      Baseline value                                                                 6.7 (1.9)                         6.7 (2.0)              6.4 (2.3) 304   6.4 (2.3) 310   6.4 (2.3) 292   6.4 (2.3) 310    6.3 (2.3) 276   6.4 (2.3) 310   6.7 (2.0) 173   6.4 (2.3) 310
      Visit value                                                                                                                             3.5 (2.7) 304   3.6 (2.8) 310   2.8 (2.4) 292   3.0 (2.5) 310    2.5 (2.4) 276   2.8 (2.6) 310   2.1 (2.3) 173   2.7 (2.6) 310
  BASDAI, 0--10 cm VAS                                                                                                                                                                                                                                        
      Baseline value                                                                 6.3 (1.7)                         6.3 (1.7)              6.0 (2.0) 304   6.0 (2.0) 310   6.0 (2.0) 292   6.0 (2.0) 310    5.9 (2.0) 276   6.0 (2.0) 310   6.3 (1.7) 173   6.0 (2.0) 310
      Visit value                                                                                                                             3.6 (2.5) 304   3.6 (2.5) 310   3.0 (2.4) 292   3.2 (2.5) 310    2.7 (2.3) 276   3.0 (2.5) 310   2.4 (2.3) 173   2.9 (2.5) 310
  C-reactive protein, mg/dl‡                                                                                                                                                                                                                                  
      Baseline value                                                                 2.2 (2.9)                         1.8 (2.2)              1.8 (2.3) 299   1.8 (2.3) 307   1.9 (2.4) 286   1.8 (2.3) 307    1.9 (2.4) 270   1.8 (2.3) 307   1.8 (2.4) 84    1.8 (2.3) 307
      Visit value                                                                                                                             0.5 (1.1) 299   0.6 (1.3) 307   0.6 (1.3) 286   0.6 (1.4) 307    0.6 (1.1) 270   0.6 (1.3) 307   0.5 (0.9) 84    0.7 (1.4) 307
  BASMI, 0--10                                                                                                                                                                                                                                                
      Baseline value                                                                 4.2 (2.1)                         3.8 (2.2)              3.9 (2.2) 296   3.9 (2.2) 309   4.0 (2.2) 255   3.9 (2.2) 310    3.9 (2.2) 273   3.9 (2.2) 310   3.9 (2.2) 173   3.9 (2.2) 310
      Visit value                                                                                                                             3.5 (2.3) 296   3.5 (2.3) 309   3.4 (2.4) 255   3.3 (2.4) 310    3.2 (2.2) 273   3.2 (2.3) 310   3.1 (2.2) 173   3.3 (2.3) 310
  Chest expansion, cm                                                                                                                                                                                                                                         
      Baseline value                                                                 3.0 (1.9)                         3.4 (1.8)              3.4 (1.9) 277   3.4 (1.9) 306   3.4 (1.8) 237   3.4 (1.9) 306    3.4 (1.9) 234   3.4 (1.9) 306   4.1 (2.1) 260   3.4 (1.9) 306
      Visit value                                                                                                                             3.8 (2.2) 277   3.8 (2.2) 277   3.7 (2.0) 237   3.7 (2.1) 306    4.1 (6.7) 234   4.0 (5.9) 306   4.1 (2.1) 260   4.0 (2.1) 306
  MASES, 0--13                                                                                                                                                                                                                                                
      Baseline value                                                                 6.7 (7.5)                         6.4 (6.8)              5.9 (7.0) 308   5.9 (7.0) 308   5.8 (6.9) 294   5.9 (7.0) 309    5.7 (6.9) 279   5.9 (7.0) 309   6.0 (7.1) 217   5.9 (7.0) 309
      Visit value                                                                                                                             3.7 (6.0) 308   3.7 (6.0) 308   2.8 (5.1) 294   3.0 (5.3) 309    2.4 (4.6) 279   2.8 (5.6) 309   2.2 (4.4) 217   2.7 (5.5) 309
  Swollen joint count, 0--44                                                                                                                                                                                                                                  
      Baseline value                                                                 1.4 (2.8)                         1.5 (3.3)              1.4 (3.1) 297   1.3 (3.0) 311   1.4 (3.1) 292   1.3 (3.0) 311    1.3 (3.1) 264   1.3 (3.0) 311   1.5 (3.2) 216   1.3 (3.0) 311
      Visit value                                                                                                                             1.1 (3.1) 297   1.2 (3.3) 311   1.0 (2.5) 292   1.1 (2.8) 311    0.9 (2.7) 264   1.1 (3.2) 311   0.8 (3.1) 216   0.9 (3.4) 311
  Tender joint count, 0--46                                                                                                                                                                                                                                   
      Baseline value                                                                 5.6 (6.8)                         5.1 (7.4)              5.1 (7.5) 297   5.1 (7.7) 311   4.8 (7.1) 292   5.1 (7.7) 311    4.4 (6.5) 264   5.1 (7.7) 311   4.9 (7.2) 218   5.1 (7.7) 311
      Visit value                                                                                                                             4.0 (7.8) 297   4.0 (7.8) 311   3.4 (7.0) 292   3.8 (7.3) 311    2.7 (5.8) 264   3.6 (7.2) 311   2.7 (6.1) 218   3.5 (7.5) 311

\*Values are the mean (SD). For observed and last observation carried forward (LOCF) analyses, the baseline value is the last observation before the first dose of adalimumab. †The majority of patients treated with placebo for the first 24 weeks of the ATLAS study did not have 2 years of exposure to adalimumab at the time of this analysis. ‡Normal range using a ultrasensitive C-reactive protein assay is 0.007--0.49 mg/dl. BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; VAS, visual analogue scale.

Adalimumab exposure {#s3c}
-------------------

Of the 311 patients who received at least one dose of adalimumab, median exposure to adalimumab was 2 years (range 14--896 days). Seventy per cent of patients (218/311) received adalimumab for at least 1.75 years. Seventy-two (23.2%) patients who were ASAS20 non-responders in the randomised, controlled portion of the study switched to adalimumab 40 mg weekly. Of these 72 patients, 53 had received weekly treatment for at least 1 year and two had received weekly adalimumab for 2 years at the time of this analysis.

Long-term efficacy {#s3d}
------------------

Treatment with adalimumab significantly reduced the signs and symptoms of AS at weeks 12 and 24. The magnitude of improvement was sustained through 2 years of adalimumab exposure ([fig 1A and B](#ard-68-06-0922-f01){ref-type="fig"}). The percentage of patients achieving ASAS20, ASAS40, ASAS 5/6 and ASAS partial remission responses was sustained from week 24 to up to 2 years of adalimumab exposure ([fig 1A and B](#ard-68-06-0922-f01){ref-type="fig"}). During short-term treatment (24 weeks of adalimumab exposure), 65.2% (202/310) of patients were ASAS20 responders, 46.1% (143/310) were ASAS40 responders, 58.6% (181/309) were ASAS 5/6 responders and 24.2% (75/310) achieved ASAS partial remission based on LOCF analyses ([fig 1B](#ard-68-06-0922-f01){ref-type="fig"}). During long-term treatment (2 years of adalimumab exposure), 64.5% (200/310) patients were ASAS20 responders, 50.6% (157/310) were ASAS40 responders, 58.9% (182/309) were ASAS 5/6 responders and 33.5% (104/310) achieved ASAS partial remission based on LOCF analyses ([fig 1B](#ard-68-06-0922-f01){ref-type="fig"}). Improvements in the individual components of the ASAS20 response evaluations were also sustained during long-term adalimumab treatment ([table 1](#ard-68-06-0922-t01){ref-type="table"}).

![Assessment in Ankylosing Spondylitis International Working Group (ASAS) responses by duration of adalimumab treatment. (A) Observed data. (B) Last observation carried forward (LOCF) data (N  =  311).](ard-68-06-0922-f01){#ard-68-06-0922-f01}

Mean values for baseline demographics and clinical characteristics for patients who switched from adalimumab 40 mg eow to 40 mg weekly were similar to mean values for the overall group of patients who received adalimumab 40 mg eow throughout ([table 2](#ard-68-06-0922-t02){ref-type="table"}), with a tendency to a somewhat greater level of disease activity at baseline. After 6 weeks of weekly adalimumab therapy, 14 of 61 (23.0%) patients had an ASAS20 response, six of 61 (9.8%) patients had an ASAS40 response and eight of 61 (13.1%) had a BASDAI 50 response. After 1 year of receiving adalimumab 40 mg weekly, 18 of 53 patients (34.0%) achieved an ASAS20 response, eight of 53 (15.1%) achieved an ASAS40 response and eight of 53 (15.1%) achieved a BASDAI 50 response (observed data); these 53 patients were ASAS non-responders before being switched to weekly adalimumab treatment.

###### Baseline demographic and clinical characteristics for patients who switched to weekly adalimumab treatment and patients who received adalimumab 40 mg every other week\*

  Characteristic                                                     Adalimumab 40 mg weekly (N  =  72)   Adalimumab 40 mg every other week (N  =  239)
  ----------------------------------------------------------------- ------------------------------------ -----------------------------------------------
  Male, n (%)                                                                    46 (63.9)                                 187 (78.2)
  White, n (%)                                                                   69 (95.8)                                 230 (96.2)
  Age, years (SD)                                                               46.1 (10.0)                                41.2 (11.8)
  Disease duration, years (SD)                                                   10.7 (9.0)                                11.1 (9.6)
  HLA-B27 positive, n (%)                                                        52 (72.2)                                 193 (80.8)
  Patient's global assessment of disease activity, cm (SD)                       7.0 (2.1)                                  6.2 (2.1)
  Total back pain, cm (SD)                                                       7.2 (2.0)                                  6.3 (2.1)
  Inflammation (mean of questions 5 and 6 of the BASDAI), cm (SD)                7.3 (1.9)                                  6.5 (2.0)
  BASFI, cm (SD)                                                                 6.1 (2.3)                                  5.2 (2.1)
  BASDAI, cm (SD)                                                                6.9 (1.6)                                  6.1 (1.7)
  C-reactive protein, mg/dl (SD)†                                                1.5 (1.6)                                  2.0 (2.7)
  BASMI, 0--10 (SD)                                                              4.5 (2.1)                                  3.8 (2.2)
  Chest expansion, cm (SD)                                                       2.9 (1.5)                                  3.4 (1.9)
  MASES, 0--13 (SD)                                                              8.4 (7.6)                                  5.9 (6.7)

\*Values are mean (SD) unless otherwise noted. †Normal range using an ultrasensitive C-reactive protein assay is 0.007--0.49 mg/dl. BASDAI, Bath Ankylosing Spondylitis Disease activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score.

Improvements in mean BASDAI scores were sustained for up to 2 years ([table 1](#ard-68-06-0922-t01){ref-type="table"}). At least a 50% improvement on the BASDAI was attained by 43.8% (133/304) of patients after 3 months of adalimumab exposure; 53.8% (157/292) after 6 months; 60.5% (167/276) after 1 year and 70.5% (122/173) after 2 years (observed data). Based on LOCF analysis, a BASDAI 50 response was attained by 42.9% (133/310) of patients after 3 months of adalimumab exposure; 51.3% (159/310) after 6 months; 55.8% (173/310) after 1 year and 58.7% (182/310) after 2 years.

Improvements in the signs and symptoms of AS were sustained during long-term adalimumab treatment ([table 1](#ard-68-06-0922-t01){ref-type="table"}). Significant reductions in CRP concentrations were sustained through 2 years of treatment. The statistically significant improvement in enthesitis (as measured by the MASES) observed during the 24-week portion of ATLAS continued to improve during 2 years of adalimumab treatment. The observed mean change in the MASES was a 3.0 point reduction after 24 weeks of adalimumab treatment compared with a 3.8 point reduction after 2 years of adalimumab treatment. Long-term adalimumab treatment was also associated with maintenance of an improvement in spinal metrology, as shown by a decrease in mean BASMI scores over time ([table 1](#ard-68-06-0922-t01){ref-type="table"}). The improvement in the overall BASMI score was driven by statistically significant improvements in three of five components of the BASMI score (eg, lumbar side flexion, cervical rotation and intermalleolar distance; p\<0.05 for each) at week 24 of the double-blind portion of the study in adalimumab compared with placebo-treated patients.[@b16] The tragus-to-wall and anterior lumbar flexion components did not respond to adalimumab treatment. Similarly, chest expansion did not change significantly in adalimumab-treated patients.

Long-term HRQoL {#s3e}
---------------

Changes over time in HRQoL assessments are summarised in [table 3](#ard-68-06-0922-t03){ref-type="table"}. Improvements based on the ASQoL were substantial and statistically significant compared with placebo by week 24 and steadily improved over time. The magnitude of improvement was more than twice the prespecified MCID of at least 1.8 points at every time point measured. Improvements in the SF-36 PCS score were substantial and exceeded the MCID of 3 points for up to 2 years of adalimumab treatment. Although the change from baseline in SF-36 MCS scores was not statistically significantly different from placebo at week 24, the mean improvement in SF-36 MCS scores also exceeded the MCID for up to 2 years of adalimumab treatment. The mean changes in SF-36 MCS scores were smaller in magnitude than the improvements in the SF-36 PCS and were stable over time.

###### Summary of mean scores of HRQoL outcomes during long-term adalimumab treatment\*

  Assessment            Baseline value at randomisation   Duration of adalimumab exposure                                                                                                                                
  -------------------- --------------------------------- --------------------------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- -----------------
  ASQoL, 0--18‡                                                                                                                                                                                                          
      Baseline value              10.6 (4.0)                        10.2 (4.0)               9.6 (4.6) 242    10.0 (4.6) 310     9.9 (4.6) 281    10.0 (4.6) 310     9.5 (4.6) 232    10.0 (4.6) 310    10.5 (4.3) 218    10.0 (4.6) 310
      Visit value                                                                            5.9 (5.1) 242     6.3 (5.2) 310     5.6 (5.0) 281     6.1 (5.3) 310     5.2 (4.8) 232     6.0 (5.2) 310     5.2 (4.9) 218     5.8 (5.2) 310
  SF-36 PCS score§                                                                                                                                                                                                       
      Baseline value              31.8 (8.0)                        32.9 (8.0)              33.8 (8.4) 237    33.1 (8.4) 304    33.1 (8.4) 278    33.2 (8.5) 308    33.8 (8.6) 227    33.2 (8.5) 308    32.1 (7.9) 214    33.2 (8.5) 308
      Visit value                                                                           41.1 (10.2) 237   40.2 (10.3) 304   42.2 (10.7) 278   41.5 (10.7) 308   43.5 (10.5) 227   41.8 (10.8) 308   43.2 (10.8) 214   41.9 (10.9) 308
  SF-36 MCS score§                                                                                                                                                                                                       
      Baseline value              44.4 (12.0)                       43.4 (12.0)             44.7 (11.5) 237   44.4 (11.7) 304   44.6 (11.4) 278   44.4 (11.6) 308   45.2 (11.2) 227   44.4 (11.6) 308   43.9 (11.1) 214   44.4 (11.6) 308
      Visit value                                                                           48.9 (10.6) 237   48.5 (10.8) 304   49.2 (10.4) 278   48.3 (10.9) 308   49.5 (10.5) 227   48.3 (11.2) 308   49.3 (10.5) 214   48.6 (11.3) 308

\*All values are the mean (SD). For observed and last observation carried forward (LOCF) analyses, the baseline value is the last observation before the first dose of adalimumab. †The majority of patients treated with placebo for the first 24 weeks of the ATLAS study did not have 2 years of exposure to adalimumab at the time of this analysis. ‡The minimum clinically important difference for the ankylosing spondylitis quality of life (ASQoL) questionnaire was a reduction of at least 1.8 points. §The minimum clinically important difference for both the Short Form 36 (SF-36) physical component summary (PCS) and mental component summary (MCS) scores was an improvement (increase) of at least 3 points. HRQoL, health-related quality of life.

Safety {#s3f}
------

Overall, adalimumab was well tolerated. The safety profile during long-term treatment was consistent with that observed during short-term treatment.[@b16] During up to 2 years of adalimumab exposure, the most common AE (reported by ⩾5% of patients) were nasopharyngitis, upper respiratory tract infection and headache ([table 4](#ard-68-06-0922-t04){ref-type="table"}). For the patients treated with adalimumab during the double-blind period and then during the open-label period, respectively, the following AE rates per 100 patient-years were observed: serious AE, 10.2 versus 10.5; serious infectious AE, 0 versus 1.1; AE leading to discontinuation, 3.8 versus 4.5 and malignant AE, 0.0 versus 0.9.

###### Adverse events reported by 5% or more of patients during up to 2 years of adalimumab treatment

  Adverse event                        Adalimumab (N  =  311) n (%)
  ----------------------------------- ------------------------------
  Nasopharyngitis                               80 (25.7)
  Upper respiratory tract infection             53 (17.0)
  Headache                                      48 (15.4)
  Arthralgia                                    33 (10.6)
  Sinusitis                                      30 (9.6)
  Fatigue                                        25 (8.0)
  Diarrhoea                                      30 (9.6)
  Nausea                                         27 (8.7)
  Influenza                                      23 (7.4)
  Cough                                          26 (8.4)
  Back pain                                      23 (7.4)
  Hypertension                                   23 (7.4)
  Pharyngolaryngeal pain                         22 (7.1)
  Bronchitis                                     20 (6.4)
  Viral infection                                19 (6.1)
  Injection-site reaction                        15 (4.8)
  Pharyngitis                                    19 (6.1)
  Rash                                           17 (5.5)

The numbers and percentages of patients who experienced TNF-associated AE of interest are summarised in [table 5](#ard-68-06-0922-t05){ref-type="table"}. There were no cases of tuberculosis, congestive heart failure, lupus-like symptoms, or demyelinating disease and no deaths were reported. There were six serious infectious AE (1.9% of patients). Of these, three were considered possibly or probably related to the study drug. One patient (0.3%) had an adalimumab-related hypersensitivity reaction. Weekly administration of adalimumab did not cause any additional safety issues ([table 4](#ard-68-06-0922-t04){ref-type="table"}).

###### Summary of TNF-associated AE of interest during up to 2 years of adalimumab treatment

  Adverse event                                    Adalimumab exposure               
  ----------------------------------------------- --------------------- ------------ -------
  Any AE                                                62 (86.1)        293 (94.2)   445.6
      At least possibly drug-related AE                 31 (43.1)        174 (55.9)   107.7
  Serious AE                                             5 (6.9)         48 (15.4)    10.5
      At least possibly drug-related serious AE             0             17 (5.5)     3.7
  AE leading to discontinuation of study drug            1 (1.4)          24 (7.7)     4.5
  Infectious AE                                         37 (51.4)        213 (68.5)   109.7
  Serious infectious AE                                  1 (1.4)          6 (1.9)      1.1
      Appendicitis                                          0             1 (0.3)      0.2
      Bacteraemia                                           0             1 (0.3)      0.2
      Beta-haemolytic streptococcal infection            1 (1.4)          1 (0.3)      0.2
      Cellulitis\*                                          0             1 (0.3)      0.2
      Pneumonia†                                            0             1 (0.3)      0.2
      Rectal abscess†                                       0             1 (0.3)      0.2
  Drug hypersensitivity-related AE                          0             1 (0.3)      0.4
  Malignancies                                           1 (1.4)          4 (1.3)      0.7
      Basal-cell carcinoma                                  0             1 (0.3)      0.2
      Malignant melanoma                                 1 (1.4)          1 (0.3)      0.2
      Non-Hodgkin's lymphoma                                0             1 (0.3)      0.2
      Squamous cell carcinoma of the skin                   0             1 (0.3)      0.2
  Injection-site reactions                               2 (2.8)         42 (13.5)    17.6
  Opportunistic infections‡                                 0             4 (1.3)      0.7
  Tuberculosis                                              0                0          0
  Demyelinating disease                                     0                0          0
  Deaths                                                    0                0          0

\*Possibly related to adalimumab treatment. †Probably related to adalimumab treatment. ‡All four cases were oral candidiasis. AE, adverse event; PY, patient-years; TNF, tumour necrosis factor.

Malignancies occurred in four patients (1.3%). One patient, a 56-year-old man, was diagnosed with non-Hodgkin lymphoma after 176 days of treatment. The non-Hodgkin lymphoma was considered by the investigator to be possibly related to the study drug. The patient was discontinued from the study and observed by his oncologist. The patient's lymph nodes regressed without chemotherapy and the patient did not require any treatment at last contact. The other three cases of malignancies included two cases of non-melanoma skin cancer (one case of squamous-cell carcinoma and one case of basal-cell carcinoma) and one case of malignant melanoma. All three patients were treated by surgical excision of the affected site.

Of the 311 patients who received at least one dose of adalimumab, 94 had a history of uveitis, seven had a history of Crohn's disease and 10 had a history of ulcerative colitis. Twelve of 311 (3.9%) patients developed uveitis during follow-up. Of these 12, three had new-onset uveitis and nine patients experienced flares. One patient with a history of ulcerative colitis had a flare of ulcerative colitis. One patient with no previous history of inflammatory bowel disease developed Crohn's disease. None of the patients with a history of Crohn's disease experienced a flare.

There were no clinically meaningful changes in clinical chemistry values, liver enzymes, or vital signs during long-term adalimumab exposure.

DISCUSSION {#s4}
==========

The placebo-controlled portion of ATLAS demonstrated that adalimumab treatment improves the signs and symptoms of AS for up to 24 weeks, beginning within 2 weeks of treatment.[@b16] ATLAS is the largest long-term study of a TNF antagonist for the treatment of active AS, with 255 patients continuing adalimumab treatment at the time of this 2-year analysis. The BASDAI 50, ASAS20, ASAS40, ASAS 5/6 and ASAS partial remission responses that were achieved during the initial 24-week, double-blind period of ATLAS were sustained for up to 2 years of treatment. Improvements in individual components of the ASAS response (patient's global assessment of disease activity, pain, function and inflammation) were also sustained for up to 2 years of adalimumab treatment.

The progressive restriction in spinal mobility experienced by patients with AS contributes to significant functional disability and reduced HRQoL. Adalimumab treatment led to sustained improvements in physical function and mobility during long-term treatment. After 2 years of adalimumab treatment, 75% of patients experienced a sustained improvement in BASMI. Not all assessments of spinal mobility that were evaluated in the ATLAS trial demonstrated a significant difference between the treatment groups. However, it is known that the tragus-to-wall, anterior lumbar flexion and chest expansion are, in general, not very responsive measures, especially not in established disease. The improvement in enthesitis (as measured by the MASES) that patients experienced at week 24 in the randomised, controlled portion of ATLAS increased in magnitude through 1 and 2 years of adalimumab treatment.

In addition, long-term adalimumab treatment was associated with improved HRQoL as demonstrated by substantial and sustained improvements assessed using a disease-specific measure (ASQoL). The improvements in SF-36 PCS scores demonstrated that adalimumab treatment is associated with an improvement in physical HRQoL that exceeded the MCID and increased over time. These HRQoL results are consistent with long-term studies of etanercept[@b11] and infliximab.[@b14] [@b28]

The ASAS20, ASAS40 and BASDAI 50 response rates after 1 year of weekly adalimumab therapy indicate that increasing the dosage of adalimumab may benefit some patients and may be considered before switching to an alternative therapy.

Adalimumab was generally well tolerated during up to 2 years of treatment. There were no unexpected safety concerns during this long-term study. Of note, patients with AS who received weekly adalimumab treatment did not experience a higher rate of AE compared with patients who received treatment eow. The overall safety profile of adalimumab is similar to other anti-TNF therapies used for the treatment of AS,[@b7] [@b9] [@b11] [@b12] [@b28] and is consistent with the safety profile of adalimumab during long-term treatment of patients with rheumatoid arthritis or psoriatic arthritis.[@b29]^--^[@b34]

CONCLUSIONS {#s5}
===========

Adalimumab treatment for up to 2 years reduced the signs and symptoms of AS and induced a partial remission. The substantial improvements in spinal mobility and enthesitis that were observed in ATLAS continued to increase during long-term therapy. The HRQoL of patients with active AS was also substantially improved during long-term adalimumab treatment. Adalimumab was generally well tolerated; the long-term safety profile was similar to the short-term safety profile. Continued evaluation of these patients will further define the long-term safety and efficacy profile of adalimumab for the treatment of patients with active AS.
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